Search Bar & Filters
Found 7 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating the effects of teplizumab compared with a placebo in individuals aged 1 to 25 years who have recently been diagnosed with Stage 3 type 1 diabetes. This Phase 3, multicenter, randomized, double-blind study aims to measure changes in blood sugar control and the ability to reduce prandial insulin use over 52 weeks. Both groups will continue their standard insulin therapy during the study. Participants will receive either teplizumab or a matching placebo through intravenous infusions, with teplizumab doses gradually increasing. The study includes two groups one receiving the study drug and the other receiving placebo infusions. The total study period for each participant lasts about 84 weeks 19 months, during which participants are closely monitored. Throughout the study, participants will be regularly evaluated for blood sugar levels, insulin use, and markers of diabetes control including glycated hemoglobin HbA1c, C-peptide levels, and glucose monitoring. Safety will be assessed by tracking adverse events and immune responses. The research team will monitor participants at specified intervals up to 78 weeks to assess treatment effects and safety.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of NNC0487-0111 for treating adults with excess body weight and type 2 diabetes. The study compares four different doses of NNC0487-0111 with a placebo, which contains no active medicine. Participants receive these treatments as weekly injections under the skin, and their group assignment is decided randomly. Participants are assigned to one of five groups four groups receive different dose levels of NNC0487-0111, and one group receives a placebo. All participants also follow a reduced-calorie diet and increase their physical activity. The injections are administered once weekly using a pre-filled pen injector to the thigh, abdomen, or upper arm. Treatment continues for 84 weeks, with ongoing monitoring. Throughout the study, participants will have their body weight, waist circumference, blood sugar control HbA1c, blood pressure, cholesterol levels, and quality of life assessed at the start and at week 84. Safety is monitored by tracking adverse events and episodes of low blood sugar up to week 88. The study lasts for about 84 weeks of treatment plus safety follow-up, and participants may undergo laboratory tests and physical exams during this time.
Actively Recruiting
Researchers are evaluating whether combining mirikizumab with tirzepatide can reduce or eliminate symptoms of moderately to severely active ulcerative colitis UC and help participants lose at least 10% of their body weight. This phase 3b study focuses on adults with UC who are also obese or overweight, comparing treatment with mirikizumab plus tirzepatide against mirikizumab plus placebo. The study is sponsored by Eli Lilly and Company and aims to better understand treatment effects on UC symptoms and weight loss. Participants receive mirikizumab first by intravenous infusion, followed by subcutaneous injections of mirikizumab. They are randomly assigned to also receive either tirzepatide or a placebo via subcutaneous injection. Treatment lasts up to 52 weeks. The study is double-blinded, so neither participants nor researchers know who receives tirzepatide or placebo during the trial. Throughout the study, participants undergo regular monitoring including clinical assessments to evaluate remission and response of UC symptoms, endoscopic exams, and histologic evaluations. Researchers measure the percentage of participants who achieve both clinical remission and significant weight loss at week 52. The total participation time is up to 61 weeks, including screening and treatment. Safety and effectiveness are closely tracked during and after treatment.
Actively Recruiting
This trial investigates the safety and effectiveness of mirikizumab combined with tirzepatide versus mirikizumab with placebo in adults who have moderately to severely active Crohns disease along with obesity or overweight. The study is a phase 3b clinical trial and aims to assess how well these treatments work together to improve disease activity and reduce weight. Participants are randomly assigned to one of two groups one receives mirikizumab intravenously followed by subcutaneous administration along with tirzepatide given subcutaneously the other group receives mirikizumab in the same way but with a placebo injection instead of tirzepatide. Treatments are given according to a defined schedule over the course of the study, which lasts up to 61 weeks. Throughout the trial, participants undergo regular monitoring including clinical assessments for Crohns disease activity, endoscopic evaluations, and measurements of body weight. Researchers track outcomes like clinical remission, endoscopic remission, and weight loss at various time points, especially at Week 52. Safety and tolerability are also carefully observed during the study period that may extend up to 61 weeks.
Actively Recruiting
Researchers are evaluating the combination of baxdrostat and dapagliflozin compared with dapagliflozin alone in adults aged 40 years and older who have type 2 diabetes, established cardiovascular disease, a history of hypertension with elevated systolic blood pressure, and at least one additional risk factor for heart failure. This phase III trial aims to assess whether adding baxdrostat can reduce the risk of heart failure events or cardiovascular death. Participants will be randomly assigned to receive either baxdrostat with dapagliflozin or placebo with dapagliflozin. Those not currently on SGLT2 inhibitors or treated for less than 4 weeks will enter a run-in period taking dapagliflozin alone for 4 to 6 weeks before randomization. Doses of baxdrostat may be increased if criteria are met. Study visits occur at 2, 4, 8, 16, and 34 weeks after randomization and then approximately every 4 months until the study ends when enough cardiovascular events have occurred. During the study, participants will have regular assessments including blood pressure and laboratory tests to monitor safety and efficacy. If participants stop the blinded study treatment early, they may continue open-label dapagliflozin. The main outcome is to see if the combination reduces heart failure events or cardiovascular death compared to dapagliflozin alone, with follow-up lasting up to 38 months. Data collection and scheduled visits will continue throughout the study period.
Actively Recruiting
This research aims to compare two asthma inhalers that use different propellants in people with mild to moderate asthma. The study evaluates whether an investigational inhaler with a new climate-friendly propellant, HFA-152a, works as safely and effectively as inhalers using the existing HFA-134a propellant. This global Phase II study plans to enroll 468 patients in Europe, Latin America, Ukraine, South Africa, and the United Kingdom. Participants will use one of three inhaler treatments in a randomized, double-blind crossover design the investigational CHF5993 pMDI with HFA-152a, CHF5993 pMDI with HFA-134a, or CHF718 pMDI with HFA-134a. Each inhaler is taken as two puffs twice daily. The study compares lung function effects of these inhalers during treatment periods. During the trial, participants will be assessed for lung function through measurements like forced expiratory volume in 1 second FEV1 at baseline and after treatment. Researchers will monitor safety, treatment adherence, and asthma control over the study period. Participants undergo scheduled visits for these evaluations, with the study expected to complete in June 2027.